1211539-82-0

Basic information

• Product Name: 2,2-Difluoro-1,3-benzodioxol-5-ol
• Synonyms: 2,2-Difluoro-1,3-benzodioxol-5-ol;2,2-difluorobenzo[d][1,3]dioxol-5-ol
• CAS NO: 1211539-82-0
• Molecular Formula: C₇H₄F₂O₃
• Molecular Weight: 174.1016664
• Mol File: 1211539-82-0.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,2-Difluoro-1,3-benzodioxol-5-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-Difluoro-1,3-benzodioxol-5-ol(1211539-82-0)
• EPA Substance Registry System: 2,2-Difluoro-1,3-benzodioxol-5-ol(1211539-82-0)

Safety Data

• Hazardous Substances Data: 1211539-82-0(Hazardous Substances Data)

Usage

Uses

2,2-Difluorobenzodioxol-5-ol is used in the preparation of isobenzofuro[6,5-f][1,3]benzodioxolones as small molecule inhibitor of insulin-like growth factor-1 receptor.

Upstream product

• 190903-71-0 (2,2-difluoro-1,3-benzodioxol-5-yl)boronic acid 
• 33070-32-5 5-bromo-2,2-difluoro-2H-1,3-benzodioxole 

Relevant articles and documents

2-(aryl (azacycloalkane-1-yl) methyl) phenol derivatives and uses thereof

The invention discloses 2-(aryl (azacycloalkane-1-yl) methyl) phenol derivatives and application thereof, and belongs to the technical field of medicines. The invention provides a compound shown in a formula I or pharmaceutically acceptable salt thereof. The series of compounds have good inhibitory activity on the histone demethylase KDM4 family in vitro, the median inhibitory concentration (IC50) of most molecules on KDM4D is less than 500 nM, and the compounds have good inhibitory effect on proliferation of various human tumor cell strains in vitro, so that the series of compounds provide a new effective choice for developing targeted histone demethylase KDM4D drugs and preparing drugs for treating and/or preventing cancers and reproductive system diseases, and have good application prospects.

SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF

The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.